Growing Prevalence of Cancer Resulting in High Unmet Need for Dendritic Cell Cancer Vaccines

Published On : 20 Dec 2016

Dendritic cells have been used as cellular mediators in clinical trials for therapeutic vaccination of cancer patients since the 1990s and this therapy has gained much prominence over the years. A report added to QYResearchReports.com carefully studies the clinical effectiveness of dendritic cell cancer vaccinations and offers sharp insights regarding the same. The 100-page research publication is titled “Global Dendritic Cell Cancer Vaccine Market Professional Survey Report 2016” and takes into consideration price, production, share, and revenue to ascertain the size of the global market. 

The prevalence of various cancers has grown tremendously worldwide, with the World Health Organization expecting the annual incidence of cancer to increase to 24 million by 2035. It was estimated that the U.S. reported approximately 1.7 million new cancer cases in 2016 alone. This alarming rise has resulted in a significant unmet need for advanced and efficient medical intervention. As of now, chemotherapy, radiation therapy, and surgery are the standard approaches to treat cancer. Researchers are, however, invested in developing newer and more effective methods, including dendritic cell cancer vaccines.

Dendritic cell cancer vaccines are considered to be safe and are known to enable antitumor immunity among cancer patients, even those with advanced symptoms. Research findings state that dendritic cell vaccines also present the hope of improving survival rates. These vaccines are used in cases of prostate cancer, melanoma, renal cell carcinoma, and malignant glioma, among others. The two most important trends positively impacting the dendritic cell cancer vaccines market are the growing combination of dendritic cell-based immunotherapy with other cancer therapies and the implementation of next-gen vaccines that enhance immunogenicity. 

To get a Sample Copy of Report visit @ http://www.qyresearchreports.com/sample/sample.php?rep_id=843330&type=E

The report includes a detailed section on the manufacturing plants of dendritic cell cancer vaccines and discusses points such as distribution of manufacturing units, date of commercial production, production capacity, sources of raw materials, technology sources, and status of research and development activities. 

The global market for dendritic cell cancer vaccines is studied on the basis of application, type, and region. By type, the market comprises Provenge, CreaVax, and Dendritic Cell Activated Cytokine Induced Killer Cells (DC-CIK). Based on region, the research report covers China, North America, Southeast Asia, Europe, India, and Japan.

There are several companies currently involved in the research and development of dendritic cell cancer vaccines. These include ImmunoCellular Therapeutics, Northwest Biotherapeutics, Creagene, Theravectys, Glaxo Smith Kline, Immunicum, Batavia Bioservices, DanDrit Biotech, Merck, DCPrime, Tella Incorporation, Vaxil BioTherapeutics, 3M Company, Elios Therapeutics, Medigene, Activartis, ImmunoCellular Therapeutics, Bellicum Pharmaceuticals, Kiromic, Argos Therapeutics, Dendreon Corporation, and SOTIO. The report takes into account some of the leading players in the dendritic cell cancer vaccines market and profiles them based on attributes such as product picture and specifications, regional distribution, sales, revenue, ex-factory price, and gross margin. 

Trending Reports :

Back To Top